Evidence map›Paper›PMID 41158157›Full record

ArticleGynecologic oncology reports2025

Successful treatment of gynecologic malignancy with trastuzumab deruxtecan in three patients with

Divya S Choudhury, Katherine C Kurnit, S Diane Yamada, Nita K Lee, Anusha Vemuri, Julieta E Barroeta, Shayan Rayani, Christopher M Straus, Gini F Fleming, Josephine S Kim

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Gynecologic oncology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Divya S ChoudhuryPritzker School of Medicine, University of Chicago, Chicago, IL, USA.
Katherine C KurnitDepartment of Obstetrics and Gynecology, Section of Gynecologic Oncology, University of Chicago Medical Center, Chicago, IL, USA.
S Diane YamadaDepartment of Obstetrics and Gynecology, Section of Gynecologic Oncology, University of Chicago Medical Center, Chicago, IL, USA.
Nita K LeeDepartment of Obstetrics and Gynecology, Section of Gynecologic Oncology, University of Chicago Medical Center, Chicago, IL, USA.
Anusha VemuriDepartment of Pathology, University of Chicago Medical Center, Chicago, IL, USA.
Julieta E BarroetaDepartment of Pathology, University of Chicago Medical Center, Chicago, IL, USA.
Shayan RayaniDepartment of Medicine, Section of Hematology/Oncology, University of Chicago Medical Center, Chicago, IL, USA.
Christopher M StrausDepartment of Radiology, University of Chicago Medical Center, Chicago, IL, USA.
Gini F FlemingDepartment of Obstetrics and Gynecology, Section of Gynecologic Oncology, University of Chicago Medical Center, Chicago, IL, USA.
Josephine S KimDepartment of Obstetrics and Gynecology, Section of Gynecologic Oncology, University of Chicago Medical Center, Chicago, IL, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objectives: Trastuzumab deruxtecan is an antibody-drug conjugate that was recently FDA-approved as second-line therapy for advanced solid tumors expressing HER2 by immunohistochemistry at the 3+ level. Clinical trials have demonstrated trastuzumab deruxtecan's promise as a treatment for advanced gynecologic malignancies, which often have poor prognoses and limited treatment options. Here, we present three HER2 negative (IHC 0) or untested patients with Methods: Consent from patients to carry out this research was obtained, and their cases were reviewed via the electronic medical record. Relevant clinical, surgical, pathologic, and imaging data are described in this report. Results: These patients with Conclusions: These cases illustrate the potential for trastuzumab deruxtecan to be useful among a broader range of patients than current guidelines include and suggest that comprehensive genomic testing is necessary to help identify patients whose disease may be susceptible to HER2-targeted therapies.

Identifiers

PMID41158157
PMCPMC12554900

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.